Fate Therapeutics Inc. buy marge
Start price
27.06.19
/
50%
€17.84
Target price
04.11.21
€82.00
Performance (%)
183.83%
End price
05.11.21
€50.64
Summary
This prediction ended on 05.11.21 with a price of €50.64. With a performance of 183.83% the BUY prediction by marge was a big success. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Fate Therapeutics Inc. | -24.008% | -24.008% | -34.414% | -94.895% |
iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by marge for this prediction
In the thread Fate Therapeutics Inc. diskutieren
marge stimmt der Buy-Einschätzung der Analysten zu
Piper Jaffray is reissuing its Buy rating on Fate Therapeutics (FATE) today, but lifting its price target seven bucks a share to $30. Piper's analyst states 'the company remains a top pick for the second half of 2019 given its "first-in-class iPSC cancer cell pipeline'.
Kursziel geändert auf 32,0
Kursziel geändert auf 82,0
In the thread Trading Fate Therapeutics Inc.
Die von marge gewählte maximale Laufzeit wurde überschritten